Decera Clinical Education Infectious Disease Podcast

Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection. In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including: High-titer convalescent plasma Corticosteroids Interleukin-6 inhibitors (eg, tocilizumab) Janus kinase inhibitors (eg, baricitinib) Present...

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including:  When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections EACS, DHHS, and IAS-USA guideline recommendati...

In this episode,  Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV. Presenter: Heiner Wedemeyer, MD Professor and Chairman Department of Gastroenterology,...

Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings, including facing up to stigma, getting access to experienced medical practitioners, and searching for information and peer support. Presenter: Paul Y. Kwo, MD Professor of Medicine Direc...

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including: Discussion of the PrEP gap and racial and gender disparities in PrEP access  CDC, EACS, and WHO guidance on PrEP eligibility  PrEP regimens currently recommended for adults and adolescents in...

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:  Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily...

In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including: • Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era • Characteristics of liver transplant recipients in the COVID-19 era • Impact of COVID-19 pandemic period on liver transplant outcomes • Impact of l...

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP). - Listen as he gives his perspectives on: - The FDA approval of long-acting cabotegravir for PrEP - Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy - Considerations for long-acting cabotegravir as PrEP Dosing...

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes: Assembly inhibitors (eg, lona...

In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including: Perinatal antiretroviral therapy exposure Investigational formulation of long-acting contraception combined with pre-exposure prophylaxis Monitoring with long-acting cabotegravir for pre-exposure prophylaxis Myocardial infarction risk by HIV stat...

In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including: Islatravir tissue and plasma distribution after monthly oral dosing Pharmacokinetics, safety, and acceptability of a tenofovir vaginal ring PrEP and Hormone Therapy in Transgender Individuals Anticholinergic drug effects in older PWH Adherence in PWH Presenters: Fideli...

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including: Epidemiology and burden of nosocomial bacterial pneumonia Patient-specific risk factors for MDR pathogens Improving outcomes with the use of antibiograms Recommended empiric therapy for clinically suspected VABP Antimicrobial resistance in HABP/VABP...

In this episode, Jordan J. Feld, MD, MPH, and Nancy Reau, MD, share lessons learned in the testing and treatment of viral hepatitis in the COVID-19 era, including: Global impact of the COVID-19 pandemic on viral hepatitis testing and linkage to care Impact of COVID-19 pandemic on testing and treatment in the United States and Canada Innovative strategies to improve linkage to care of patients with...

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP). Listen as he gives his perspectives on the: PrEP pipeline and the importance of having options for patients with differing preferences FDA approval of long-acting cabotegravir for PrEP HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabi...

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including: Prevention strategies LA therapies Second-line therapies The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate w...

In this episode, Jason Schafer, PharmD, MPH, explores recommendations and data on managing antiretroviral therapy (ART) in the inpatient setting. Listen as he gives his perspectives on: Antiretroviral stewardship to prevent medication errors in the inpatient setting and at transitions of care Renal and hepatic dosing considerations for ART Drug–drug interaction considerations between ART and medic...

Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV. Presenters: Heiner Wedemeyer, MD Professor and Chair...

Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around...

Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include: Bulevirtide Interferon λ Lonafarnib Presenters: Nancy Reau,...

In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B. The conversation focuses on the stigma many patients experience following diagnosis and how access to treatment may reduce this. Presenter: Robert G. Gish, MD Professor of Med...

In this episode, Drs Norah Terrault, MD, MPH, and Grace LH Wong, MD, share lessons learned in the care of patients with hepatitis B virus (HBV) in the COVID-19 era, including: HBV cascade of care before vs during the pandemic Innovative strategies to improve HBV diagnosis and linkage to care Lessons learned in telemedicine Elimination through vaccination Management of HBV and COVID-19 coinfection...

In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses what is known about the SARS-CoV-2 omicron variant, including: Transmissibility and infectiousness  Immune evasion Disease severity  Risks of hospitalization and death   Vaccine effectiveness   2- vs 3-dose vaccine effectiveness T-cell response Presenter:   Sharon R. Lewin, AO, FRACP, PhD, FAHMS Director , The Peter Doherty Institu...

In episode 6 of an ongoing series of sharing sessions between a physician and patient, Tarik Asselah, MD, PhD, and his patient, who is living with chronic hepatitis B (CHB), discuss: Importance and goals of hepatitis B virus (HBV) treatment, with a call for broader access to treatment worldwide Screening for HBV, especially given the frequency of asymptomatic disease HBV vaccination as a preventiv...

In this episode, Mark S. Sulkowski, MD, explores recommendations and data on treating HIV and hepatitis C virus (HCV) in patients who are coinfected. Listen as he gives his perspectives on: Prioritization of both HIV and HCV treatment Efficacy of HCV direct-acting antivirals in people with HIV American Association for the Study of Liver Diseases/Infectious Diseases Society of America recommendatio...

In this episode, Mark S. Sulkowski, MD, discusses his recommended approach for managing nonalcoholic steatohepatitis in patients with HIV, including recognizing nonalcoholic steatohepatitis, recommending lifestyle interventions, and considering pharmacologic approaches.  Presenter: Mark S. Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Chief, Infectious Disease Johns...